Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Patients Must~1. Between 16- 75 years of age.~2. Male or, if female, physiologically incapable of childbearing or utilizing birth control.~3. Have current diagnosis of symptom-limited NYHA Functional Class III/IV PAH that is:~   * PPH (idiopathic or familial PAH); or~  * PAH associated with collagen vascular disease (confirmed by antinuclear antibody titer or acceptable test); or~  * PAH associated with HIV infection (confirmed by serological test).~4. If HIV positive, have CD4 lymphocyte count ≥ 200 at baseline and receiving current SOC anti-retroviral or effective medication for HIV infection.~5. Optimally treated with conventional PH therapy and clinically stable for at least 1 month prior to baseline.~6. Have ventilation/perfusion scan, contrast-enhanced CT scan, or pulmonary angiogram after onset of PAH that rules out pulmonary embolism.~7. Have cardiac catheterization in last 3 months (or at Baseline) showing:~   * PAPm \> 35 mmHg (at rest) \&~  * PCWPm (or LV end diastolic pressure) \< 16 mmHg \&~  * PVR \> 5 mmHg/L/min.~8. Have echocardiogram in last 3 months consistent with PH, specifically:~   * evidence of RV hypertrophy or dilation \&~  * evidence of normal LV function \&~  * absence of mitral valve stenosis.~9. Have chest radiograph consistent with PH performed in last 3 months. Radiograph must show clear lung fields or no more than patchy interstitial infiltrates.~10. Unless contraindicated, able to receive one of following anticoagulants: warfarin to achieve INR between 1.5-2.5 or heparin to produce aPTT between 1.3-1.5 times control, unless higher levels clinically indicated.~11. Mentally and physically capable of learning to administer Study Drug using ambulatory intravenous infusion pump and central venous access, or have trained caregiver.~12. If on corticosteroids, receiving stable dose of 20 mg/day of prednisone (or equivalent dose of another steroid) for at least 1 month prior to entry.~Exclusion Criteria: Patients must not:~1. Nursing or pregnant (women of childbearing potential have negative pregnancy test).~2. Have had new type of chronic therapy (including but not limited to oxygen, different category of vasodilator, diuretic, digoxin) for PH, except for anticoagulants, added in last month.~3. Be scheduled for heart-lung transplant.~4. Have any PH medication except for anticoagulants discontinued in week prior to study entry.~5. Have received any chronic prostaglandin or prostaglandin analogue (including intravenous/inhaled/oral: epoprostenol, iloprost, beraprost, etc.), any phosphodiesterase inhibitor therapy such as sildenafil, or any endothelin antagonist therapy such as bosentan, in past 30 days.~6. Have PH associated with chronic thromboembolic disease; or chronic obstructive lung diseases or hypoxemia; or evidence of significant parenchymal lung disease as evidenced by PFTs in last 3 months as follows (any one of following):~   * TLC \< 60% (predicted) or high resolution CT documenting diffuse interstitial fibrosis or alveolitis~  * FEV1/FVC ratio \< 50%~7. Have Portal Hypertension.~8. Have history of uncontrolled Sleep Apnea, defined as oxygen desaturation less than 90% at night, in past 3 months.~9. Have history of left-sided heart disease including:~   * Aortic or mitral valve disease or~  * Pericardial constriction or~  * Restrictive or congestive cardiomyopathy; or have evidence of current left-sided heart disease defined by:~  * PCWPm or LV end diastolic pressure \> 16 mmHg or~  * LVEF \< 40% by MUGA, angiography or echocardiography or~  * LV Shortening Fraction \< 22% by echocardiography or~  * Symptomatic coronary disease (demonstrable ischemia).~10. Have any disease other than HIV or connective tissue disease associated with PH (e.g. sickle cell anemia, schistosomiasis).~11. Have active AIDS or tuberculosis.~12. Have musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease thought to limit ambulation, or connected to machine which is not portable.~13. Have baseline exercise capacity of \<50 m or \>325 m as measured by 6-Minute Walk Test.~14. Have uncontrolled systemic hypertension as evidenced by systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg.~15. Have used prescription appetite suppressants in 3 months of study entry.~16. Have chronic renal insufficiency defined by creatinine \>2.5 mg/dL or requiring dialysis.~17. Receiving an investigational drug (other than acute challenge with epoprostenol), have in place an investigational device, or have participated in investigational drug/device study in past 30 days.~18. Have presence of any physiological or mental condition which contraindicates administration of Remodulin.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues